
|Articles|April 12, 2018
Ipsos Healthcare Releases Pan-Cancer Testing Monitor in Australia
Advertisement
Ipsos Healthcare-the global healthcare business of Ipsos-announced the expansion of its syndicated Pan-Cancer Testing Monitor (PCTM) to the Australian market.
The study gathers insights from medical oncologists and pathologists on topics such as awareness and current utilization of pan-cancer tests, perceived advantages and disadvantages, and drivers and barriers to use. In addition, it incorporates de-identified patient record forms for patients who were recently tested with a pan-cancer test.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Why High-Risk Patients Still Need Antivirals: Q&A with Gurinder S. Sidhu, M.D.
2
Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising, Alleging Misleading Dosing Comparisons
3
A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims
4
Developing Better Drugs, Not Just More Drugs: Q&A with David Hung
5




